Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…

You can get access to the report by clicking here now…

Joseph C. Galante net worth and biography

Joseph Galante Biography and Net Worth

Director of Cumberland Pharmaceuticals

Mr. Galante is a music industry executive with extensive experience that scans a celebrated career. He is accredited with developing the careers of Alabama, Dave Mathews Band, Dolly Parton, Kenny Chesney, Brad Paisley, Martina McBride, Carrie Underwood, Clint Black, Miranda Lambert, and the Judds, among others. His successful business track record, entrepreneurial and public company experience make him a valuable member of our board. Mr. Galante began at RCA Records in New York, followed by a transfer to RCA Nashville where he served as a director at the label, followed by the role of Vice President of Promotion and Marketing. At the age of 32 he became the youngest person ever named to run a major country record label. In 1990 he was appointed President of RCA Records US based in New York. He returned to Nashville as Chairman to run the RCA and BNA labels in Nashville. Under his leadership, RCA Records was the number one country label for eleven consecutive years. He then served as Chairman of Sony Music Nashville for six years. He was presented with the Bob Kingsley Living Legend Award by the Opry Trust to honor his work for country music. Mr. Galante is currently a member of the Board of Directors of Pinnacle Financial Partners whose shares are listed on the NASDAQ stock exchange, the Country Music Association, and serves as the Chair of the CMA Foundation.

What is Joseph C. Galante's net worth?: The estimated net worth of Joseph C. Galante is at least $51,093.16 as of January 20th, 2023. Mr. Galante owns 22,508 shares of Cumberland Pharmaceuticals stock worth more than $51,093 as of December 22nd. This net worth approximation does not reflect any other investments that Mr. Galante may own. Learn More about Joseph C. Galante's net worth.
How do I contact Joseph C. Galante?: The corporate mailing address for Mr. Galante and other Cumberland Pharmaceuticals executives is 2525 WEST END AVENUE SUITE 950, NASHVILLE TN, 37203. Cumberland Pharmaceuticals can also be reached via phone at (615) 255-0068 and via email at [email protected]. Learn More on Joseph C. Galante's contact information.
Has Joseph C. Galante been buying or selling shares of Cumberland Pharmaceuticals?: Joseph C. Galante has not been actively trading shares of Cumberland Pharmaceuticals in the last ninety days. Most recently, on Friday, October 29th, Joseph C. Galante bought 142 shares of Cumberland Pharmaceuticals stock. The stock was acquired at an average cost of $2.72 per share, with a total value of $386.24. Learn More on Joseph C. Galante's trading history.
Who are Cumberland Pharmaceuticals' active insiders?: Cumberland Pharmaceuticals' insider roster includes Martin Cearnal (SVP), Joseph Galante (Director), A. J. Kazimi (CEO), A.J. Kazimi (CEO), Kenneth Krogulski (Director), and William Sumas (EVP). Learn More on Cumberland Pharmaceuticals' active insiders.

Joseph C. Galante Insider Trading History at Cumberland Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/29/2021	Buy	142	$2.72	$386.24
10/27/2021	Buy	142	$2.61	$370.62
10/25/2021	Buy	142	$2.64	$374.88
10/22/2021	Buy	142	$2.66	$377.72
10/20/2021	Buy	142	$2.63	$373.46
10/18/2021	Buy	142	$2.75	$390.50
10/15/2021	Buy	142	$2.76	$391.92
10/13/2021	Buy	142	$2.71	$384.82
10/11/2021	Buy	142	$2.73	$387.66
10/8/2021	Buy	142	$2.84	$403.28
10/6/2021	Buy	142	$2.76	$391.92
10/4/2021	Buy	142	$2.87	$407.54
10/1/2021	Buy	142	$2.69	$381.98
9/29/2021	Buy	142	$2.82	$400.44
9/27/2021	Buy	142	$2.79	$396.18
9/24/2021	Buy	142	$2.74	$389.08
9/22/2021	Buy	142	$2.76	$391.92
9/20/2021	Buy	142	$2.82	$400.44
9/17/2021	Buy	142	$2.85	$404.70
9/15/2021	Buy	142	$2.86	$406.12
9/13/2021	Buy	142	$2.96	$420.32
9/9/2021	Buy	142	$2.77	$393.34
9/7/2021	Buy	142	$2.79	$396.18
9/3/2021	Buy	142	$2.85	$404.70
9/1/2021	Buy	142	$2.88	$408.96
8/26/2020	Buy	225	$3.29	$740.25	20,992
8/21/2020	Buy	375	$3.35	$1,256.25	20,992
8/14/2020	Buy	375	$3.44	$1,290.00	20,992
8/7/2020	Buy	375	$3.42	$1,282.50	20,992
7/31/2020	Buy	375	$3.26	$1,222.50	20,992
7/24/2020	Buy	375	$3.33	$1,248.75	20,992
7/17/2020	Buy	375	$3.29	$1,233.75	20,992
7/10/2020	Buy	375	$3.31	$1,241.25	20,992
7/2/2020	Buy	300	$3.34	$1,002.00	20,992
6/26/2020	Buy	375	$3.37	$1,263.75	20,992
6/19/2020	Buy	375	$3.41	$1,278.75	20,992
6/12/2020	Buy	225	$3.37	$758.25	20,992
6/8/2020	Buy	75	$3.54	$265.50	17,767
6/5/2020	Buy	75	$3.44	$258.00	17,767
6/3/2020	Buy	75	$3.29	$246.75	17,767
6/1/2020	Buy	75	$3.45	$258.75	17,767
5/28/2020	Buy	75	$3.34	$250.50	17,767
5/26/2020	Buy	75	$3.59	$269.25	17,767
5/22/2020	Buy	75	$3.61	$270.75	17,767
5/20/2020	Buy	75	$3.77	$282.75	17,767
5/18/2020	Buy	75	$3.82	$286.50	17,767
5/15/2020	Buy	75	$3.76	$282.00	17,767
5/13/2020	Buy	150	$3.93	$589.50	17,767
5/11/2020	Buy	150	$4.02	$603.00	17,767
5/7/2020	Buy	150	$3.97	$595.50	17,767
5/5/2020	Buy	150	$3.99	$598.50	17,767
5/1/2020	Buy	150	$4.01	$601.50	17,767
4/29/2020	Buy	150	$4.01	$601.50	17,767
4/27/2020	Buy	150	$4.02	$603.00	17,767
4/23/2020	Buy	150	$4.03	$604.50	17,767
4/21/2020	Buy	150	$4.03	$604.50	17,767
4/17/2020	Buy	150	$4.04	$606.00	17,767
4/15/2020	Buy	150	$4.05	$607.50	17,767
4/13/2020	Buy	75	$4.03	$302.25	17,767
7/24/2019	Buy	1,680	$6.23	$10,466.40	11,618
6/12/2019	Buy	1,682	$6.36	$10,697.52	9,975
4/4/2019	Buy	241	$6.19	$1,491.79	8,732
4/1/2019	Buy	382	$5.99	$2,288.18	8,732

Joseph C. Galante Buying and Selling Activity at Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Company Overview

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Today's Range

Now: $2.27

$2.25

$2.39

50 Day Range

MA: $1.40

$1.06

$2.44

2 Week Range

Now: $2.27

$1.04

$3.05

Volume

188,828 shs

Average Volume

472,673 shs

Market Capitalization

$31.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.3

The #1 Coin for November 2024

From Crypto 101 Media | Ad